Skip to main content

Table 2 Results from Five Published Clinical Trials

From: Informative noncompliance in endpoint trials

Trial Acronym

Experimental Treatment

Control Treatment

Patient Population

Endpoint

Sample Size

Endpoint Number

and Rate

Discontinuation Number

and Rate

Hazard Ratio Associated with Non-compliance

p-value

SOLVD-T

Enalapril

Placebo

Left Ventricular Dysfunction with Overt Heart Failure

Total Mortality

2,569

961 (37.4%)

839 (32.7%)

2.7

< 0.0001

SOLVD-P

Enalapril

Placebo

Left Ventricular Dysfunction without Overt Heart Failure

Total Mortality

4,228

638 (15.1%)

987 (23.3%)

3.2

< 0.0001

RENAAL

Losartan

Placebo

Type 2 Diabetes with Nephropathy

Doubling of Serum Creatinine, End-Stage Renal Disease or Death

1,513

686 (45.3%)

469 (31.0%)

2.6

< 0.0001

LIFE

Losartan

Atenolol

Hypertension and Left Ventricular Hypertrophy

Myocardial Infarction, Stroke or Cardiovascular Death

9,193

1096 (11.9%)

2,273 (24.7%)

2.6

< 0.0001

OPTIMAAL

Losartan

Captopril

High-Risk Acute Myocardial Infarction

Total Mortality

5,477

946 (17.3%)

1,156 (21.1%)

5.0

< 0.0001